PD TFEB Activator and Lysosomal Biogenesis Companies
📖 Wiki Page
company823 wordssynced 2026-04-02
Overview
This category covers biotechnology and pharmaceutical companies developing TFEB (Transcription Factor EB) activators and lysosomal biogenesis therapeutics for Parkinson's disease. These approaches target the master regulatory pathway for cellular clearance, enhancing the cell's ability to clear toxic protein aggregates, damaged mitochondria, and lipid deposits through enhanced autophagy and lysosomal function.
TFEB is the master regulator of the CLEAR (Coordinated Lysosomal Expression and Regulation) network. In Parkinson's disease, TFEB activity is suppressed due to hyperactive mTORC1 signaling, which keeps TFEB phosphorylated and sequestered in the cytoplasm. This impairs the cell's ability to clear alpha-synuclein aggregates and contributes to neurodegeneration.
Pathway / Mechanism Diagram
graph TD
A["mTORC1 Active"] --> B["TFEB Phosphorylation"]
B --> C["TFEB Cytoplasmic Retention"]
D["Starvation / Lysosomal Stress"] --> E["mTORC1 Inhibition"]
E --> F["Calcineurin Activation"]
F --> G["TFEB Dephosphorylation"]
G --> H["TFEB Nuclear Translocation"]
H --> I["CLEAR Network Activation"]
I --> J["Lysosomal Biogenesis"]
I --> K["Autophagy Genes"]
I --> L["Lipid Catabolism"]
J --> M["Enhanced Aggregate Clearance"]
K --> M
M --> N["Abeta and Tau Clearance"]
N --> O["Neuroprotection"]
style H fill:#1b5e20,color:#e0e0e0
style O fill:#1b5e20,color:#e0e0e0
style C fill:#5d4400,color:#e0e0e0
Key Companies
TFEB Activation and Autophagy Enhancement
...
Overview
This category covers biotechnology and pharmaceutical companies developing TFEB (Transcription Factor EB) activators and lysosomal biogenesis therapeutics for Parkinson's disease. These approaches target the master regulatory pathway for cellular clearance, enhancing the cell's ability to clear toxic protein aggregates, damaged mitochondria, and lipid deposits through enhanced autophagy and lysosomal function.
TFEB is the master regulator of the CLEAR (Coordinated Lysosomal Expression and Regulation) network. In Parkinson's disease, TFEB activity is suppressed due to hyperactive mTORC1 signaling, which keeps TFEB phosphorylated and sequestered in the cytoplasm. This impairs the cell's ability to clear alpha-synuclein aggregates and contributes to neurodegeneration.
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Key Companies
TFEB Activation and Autophagy Enhancement
Lyterian Therapeutics
Focus: mTOR-independent TFEB activation and autophagy enhancement
Lead Candidate: LT-002
Indication: Parkinson's disease
Stage: Preclinical
Mechanism: Small molecule activators that promote TFEB nuclear translocation without mTOR inhibition
Mechanism: Small molecule agonists of lysosomal cation channels to enhance autophagy-lysosomal function through calcium signaling, which intersects with TFEB pathway activation
The following diagram shows the key molecular relationships involving PD TFEB Activator and Lysosomal Biogenesis Companies discovered through SciDEX knowledge graph analysis: